- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03477175
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Melbourne, Australia, 3004
- The Alfred Hospital
-
-
-
-
Antwerpen
-
Edegem, Antwerpen, Belgium, 2650
- UZ Antwerpen
-
-
Brussels
-
Bruxelles, Brussels, Belgium, 1200
- Cliniques Universitaires Saint-Luc
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Sun Yat-sen University, Cancer Center
-
-
Guangxi
-
Guilin, Guangxi, China
- Affiliated Hospital of Guilin Medical University
-
-
Heilongjiang
-
Haerbin, Heilongjiang, China
- Harbin Medical University Cancer Hospital
-
-
Henan
-
Zhengzhou, Henan, China
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Hunan
-
Changsha, Hunan, China
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Jiangsu Cancer Hospital
-
Nanjing, Jiangsu, China
- Nanjing First Hospital
-
-
Jilin
-
Changchun, Jilin, China
- The First Hospital of Jilin University
-
-
Shanghai
-
Shanghai, Shanghai, China
- No.10 People of Shanghai
-
-
Sichuan
-
Chengdu, Sichuan, China
- West China School of Medicine/West China Hospital, Sichuan University
-
-
Tianjin
-
Tianjin, Tianjin, China
- Tianjin Medical University Cancer Institute & Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Zhejiang Cancer Hospital
-
-
-
-
-
Essen, Germany, 45147
- Eisai Trial Site 2
-
Würzburg, Germany, 97080
- Eisai Trial Site 1
-
-
-
-
Toscana
-
Pisa, Toscana, Italy, 56124
- Azienda Ospedaliero Universitaria Pisana
-
-
-
-
-
Seoul, Korea, Republic of, 6351
- Samsung Medical Center - PPDS
-
-
Gyeonggido
-
Goyang-si, Gyeonggido, Korea, Republic of, 10408
- National Cancer Center
-
-
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1066 CX
- Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis
-
-
-
-
-
Gliwice, Poland, 44-101
- Centrum Onkologii Instytut im.Marii Sklodowskiej Curie-Oddzial w Gliwicach
-
-
-
-
-
Bucharest, Romania, 11863
- Institutul National de Endocrinologie "C. I. Parhon"
-
-
-
-
Krung Thep Maha Nakhon
-
Pathum Wan, Krung Thep Maha Nakhon, Thailand, 10330
- Chulalongkorn University
-
-
-
-
California
-
Torrance, California, United States, 90502
- Harbor UCLA Medical Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
It is required for all participants currently participating in other lenvatinib studies to meet the following eligibility criteria.
- Provide signed written informed consent for the roll-over study
- Currently enrolled in an Eisai-sponsored lenvatinib clinical study and still receiving at least one of the study drugs from that protocol
- Currently deriving clinical benefit from at least one of the study drug(s) as determined by the investigator
- Must be able and willing to comply with the current roll-over protocol requirements
- Continued ability to swallow and retain orally administered study drug(s)
- Does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
- Women of childbearing potential and men with reproductive potential (if specified by the parent study) must be willing to continue to use highly effective methods of contraception as per local practices of standard of care during the period of the study
- Women of childbearing potential must have a negative serum pregnancy test at the time of transition to the study and before continuing study drug(s)
Exclusion Criteria:
- Permanent discontinuation of all study drug(s) in the parent study due to toxicity or disease progression and without clinical benefit
- Receiving any prohibited medication(s) as described in the parent study
- Any unresolved toxicity that meets the criteria for study drug(s) discontinuation or withdrawal criteria from the parent study at the time of transition to this study
- Uncontrolled diabetes, hypertension or other medical conditions at the time of transition to the roll-over study that may interfere with assessment of toxicity
- Pregnant or lactating female
- Any serious and/or unstable pre-existing medical condition, psychiatric disorder or other conditions at the time of transition to the roll-over study that could interfere with participant's safety in the opinion of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A : Lenvatinib
The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib monotherapy or who crossed over from a comparator arm to receive lenvatinib monotherapy in their parent study will continue to receive lenvatinib monotherapy.
|
Oral Administration.
Other Names:
|
Experimental: Cohort B: Lenvatinib plus Comparator drug
The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received lenvatinib combination therapy or who crossed over from a comparator arm to receive lenvatinib combination therapy in their parent study will continue to receive lenvatinib combination therapy.
|
Oral Administration.
Other Names:
Per parent study.
|
Experimental: Cohort C: Comparator drug
The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive comparator treatment, with exception of participants receiving placebo. For China only: The roll-over eligible participants from Eisai-sponsored lenvatinib studies who received comparator treatment in their parent study will continue to receive sorafenib, with exception of participants receiving placebo. |
Per parent study.
Per parent study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with any treatment-emergent (TE) serious adverse event (SAE)
Time Frame: Up to 28 days after the last dose of study drugs or 5 × half-life of study drugs, whichever is longer (up to 10 years)
|
Up to 28 days after the last dose of study drugs or 5 × half-life of study drugs, whichever is longer (up to 10 years)
|
Number of participants with any non-serious TE adverse event (TEAE)
Time Frame: Up to 28 days after the last dose of study drugs or 5 × half-life of study drugs, whichever is longer (up to 10 years)
|
Up to 28 days after the last dose of study drugs or 5 × half-life of study drugs, whichever is longer (up to 10 years)
|
Number of Participants With any Serious Treatment-emergent Adverse Event (TEAE)
Time Frame: Up to 28 days after the last dose of study drugs or 5*half-life of study drugs, whichever is longer (approximately 43 months)
|
Up to 28 days after the last dose of study drugs or 5*half-life of study drugs, whichever is longer (approximately 43 months)
|
Number of Participants With any TEAE
Time Frame: Up to 28 days after the last dose of study drugs or 5*half-life of study drugs, whichever is longer (approximately 43 months)
|
Up to 28 days after the last dose of study drugs or 5*half-life of study drugs, whichever is longer (approximately 43 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E7080-G000-604
- 2017-003668-11 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
NeuPharma, Inc.RecruitingLocally Advanced Solid Tumors | Metastatic Solid TumorsUnited States
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
Clinical Trials on E7080
-
Emory UniversityNational Cancer Institute (NCI); Eisai Co., Ltd.RecruitingUnresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Emory UniversityEisai Inc.TerminatedDifferentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMetastatic Adrenal Gland Pheochromocytoma | Malignant Adrenal Gland Pheochromocytoma | Malignant ParagangliomaUnited States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Primary Peritoneal High Grade Serous Adenocarcinoma | High Grade Ovarian Serous Adenocarcinoma | Recurrent High Grade Fallopian Tube Serous Adenocarcinoma | Recurrent High Grade Ovarian Serous Adenocarcinoma | High Grade Fallopian Tube Serous Adenocarcinoma | Peritoneal High Grade...United States
-
M.D. Anderson Cancer CenterRecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States
-
Eisai Co., Ltd.CompletedHepatocellular CarcinomaJapan, Korea, Republic of
-
Eisai Inc.CompletedHepatic Impairment | Hepatic FunctionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPoorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8United States
-
Eisai Inc.CompletedKIF5B-RET-Positive Adenocarcinoma of the LungUnited States, Hong Kong, Japan, Taiwan, Singapore
-
Eisai Inc.Approved for marketingDifferentiated Thyroid CancerUnited States